It has been shown that interleukin 18 (IL-18) exerts antitumor activity. In this study, we investigated whether oncolytic adenovirusmediated gene transfer of IL-18 could induce strong antitumor activity. A tumor-selective replicating adenovirus expressing IL-18 (ZD55-IL-18) was constructed by insertion of an IL-18 expression cassette into the ZD55 vector, which is based on deletion of the adenoviral E1B 55-kDa gene. It has been shown that ZD55-IL-18 exerted a strong cytopathic effect and significant apoptosis in tumor cells. ZD55-IL-18 significantly decreased vascular endothelial growth factor and CD34 expression in the melanoma cells. Treatment of established tumors with ZD55-IL-18 showed much stronger antitumor activity than that induced by ZD55-EGFP (enhanced green fluorescent protein) or Ad-IL-18. These data indicated that oncolytic adenovirus expressing IL-18 could exert potential antitumor activity through inhibition of angiogenesis and offer a novel approach to melanoma therapy.
Introduction
Interleukin 18 (IL-18) was first described as a novel cytokine that stimulated interferon-g (IFN-g) production by T and natural killer (NK) cells. 1 Besides its IFNinducing activity, IL-18 also augments NK cells activity 2 and cytolytic T lymphocyte development, 3 stimulates Fasligand-mediated tumor cell cytotoxicity by NK cells 4 and enhances the production of T helper 1 type cytokines, 5 which are known to be associated with cell-mediated immunity and antitumor responses. Furthermore, IL-18 has been shown to have potent antitumor effects that are mediated by induction of apoptosis 6 and inhibition of angiogenesis. 7 Recently, several reports have shown that IL-18 has potent antitumor effects when administered in animal models of lung cancer, breast cancer, sarcoma and melanoma in vivo. [7] [8] [9] [10] [11] In these models, systemic administration of IL-18 9, 12 or in vivo IL-18 gene transfer 13, 14 inhibited tumor growth and prolonged the survival of tumor-bearing mice. The antitumor effects of IL-18 in multiple animal models provided the rationale for investigation of recombinant human (rh) IL-18 in clinic cancer immunotherapy. In 2006, Robertson et al. 15 described the results of the first clinical trial of rhIL-18 in patients with melanoma. Although the aims of this phase I clinical trial are to investigate the toxicity, pharmacokinetics and biological activities of rhIL-18 in patients, it is interesting to note that of the six patients enrolled in the trial, tumor regression was observed in a patient with metastatic melanoma after rhIL-18 treatment. In the absence of any other therapy, the nodular lesions were regressed by 69% on computed tomography scans taken 3 months after the last dose of rhIL-18. However, IL-18 most closely resembles IL-12, as both are pro-inflammatory cytokines. Systemic administration of recombinant IL-12/IL-18 causes dose-dependent adverse effects in mice and humans. 16, 17 IFN-g production brings about an acute systemic inflammatory response with marked injury to some particular organs, especially the liver, 18 which may ultimately prevent the widespread clinical application of this recombinant protein.
The introduction of IL-18 gene into tumor cells provides a safe and efficient method to reduce adverse effects for cytokine therapy treatment. Osaki et al. 19 showed that direct injection of an IL-18 adenoviral (Ad) vector into tumor elicited an effective immune response as well as potent antitumor effects. Ad vectors have been extensively used for trans-immunogene delivery into tumors in cancer gene therapy. For safety reasons, firstgeneration Ad vectors were rendered replication-deficient by deleting essential viral genes, such as those of the E1 region. However, a major limitation of cancer gene therapy is the inadequacy of replication-deficient Ad vectors to efficiently infect tumors, 20 which may limit their antitumor activity. To solve this problem, adenovirus mutants that preferentially replicate in and lyse tumor cells, known as oncolytic adenoviruses, may be very suitable for cytokine gene transfer. The most studied oncolytic adenovirus is an adenovirus with the E1B 55-kDa gene deleted to attenuate viral replication and cytolysis in normal tissues but not in tumor cells. 21 Such in situ amplification may allow for relatively low, nontoxic doses to be highly effective in elimination of cancer cells and solid tumors. To our knowledge, however, there is no report in which IL-18 gene was delivered into tumors by means of the E1B 55kDa-deficient oncolytic adenovirus.
In this study, we used ZD55-IL-18, an E1B 55kDa-deficient adenovirus armed with IL-18 gene, to transfer IL-18 into the tumor cells. The antitumor and antiangiogenic activity mediated by ZD55-IL-18 was studied in human melanoma cell lines and in melanoma-bearing nude mice. We showed that ZD55-IL-18 acts as an angiogenesis inhibitor and a tumor suppressor, which is sufficiently potent to suppress angiogenesis and tumor growth in vivo. These results indicate that ZD55-IL-18 can be used as a potential therapeutic strategy for treatment of human melanoma.
Materials and methods

Cell lines and culture conditions
The human melanoma cell line A375 was purchased from the Shanghai Cell Collection (Shanghai, China). Human embryonic kidney (HEK)293 cell line was obtained from Microbix Biosystems (Toronto, ON, Canada). The HEK293 cells were cultured in Dulbecco's modified essential medium containing 10% fetal bovine serum (GIBCO-BRL, Gaithersburg, MD), 4 mM L-glutamine, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin at 37 1C in a humidified atmosphere with 5% CO 2 . A375 cells were routinely maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin and 2 mM L-glutamine.
Virus construction and production pZD55, the E1B TdT-mediated dUTP-biotin nick end-labeling assay The TdT (terminal deoxynucleotidyl transferase)-mediated dUTP-biotin nick end-labeling assay (TUNEL) technique was performed to detect and to quantitate apoptotic cell death using the In Situ Cell Death Detection Kit (Roche, Indianapolis, IN) following the manufacturer's instructions. Briefly, chamber slides were fixed with 4% paraformaldehyde and permeabilized in 0.1% Triton X-100. Then the slides were incubated with TUNEL reaction mixture for 1 h at 37 1C. After washing with phosphate-buffered saline (PBS), the slides were incubated with a peroxidase-conjugated antibody for 30 min at 37 1C and were developed using DAB (3,3 0 -diaminobenzidine) system. Under microscopy, six fields were randomly selected from every sample, and independent observers performed cell counting in a blind manner. The apoptotic rate ¼ (number of total apoptotic cells/total number of cells) Â 100%.
Xenograft tumor model in nude mice animals
Male BALB/c nude mice at 4-5 weeks old were obtained from the Shanghai Experimental Animal Center of the Chinese Academy of Sciences (Shanghai, China) and quarantined for a week before tumor implantation. Animal welfare and experimental procedures were carried out strictly in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996) . The xenograft tumor model was established by subcutaneously injecting A375 cells (2 Â 10 6 ) into the right flank of mice. The tumors reached a volume of 100-120 mm 3 after 2 weeks, mice were divided randomly into four groups (eight mice per group) and were treated by intratumoral injections of ZD55-IL-18, ZD55-EGFP and AD-IL-18 (7 Â 10 8 PFU (plaque-forming units) per dose every day) for three consecutive days or treated with PBS as a control. The tumor was monitored every week by measuring tumor size using caliper for 49 days. The tumor volume was calculated by the following formula: V (mm 3 ) ¼ length Â width 2 /2. At the end of the experiment, tumors were harvested for additional analyses as described below. Differences in tumor growth were tested for statistical significance.
Immunohistochemistry staining
Tumors were harvested and fixed in 10% formalin, embedded in paraffin and sliced 4-mm-thick sections. Deparaffinized tumor sections were treated with 3% H 2 O 2 for 10 min to block the endogenous peroxidase and incubated with blocking serum (goat serum) at room temperature for 30 min. After being washed thrice with PBS, the sections were then incubated for 60 min at room temperature with anti-IL-18 antibody, anti-CD34, anti-VEGF (vascular endothelial growth factor) or anti-E1A (dilution 1:200). After being rinsed with PBS for 5 min, the sections were incubated with a biotinylated secondary antibody for 20 min. After being washed with PBS for 5 min, the slides were incubated with the avidin-biotin complex for 30 min. Chromogen was developed with 10 mg of 3,3 0 -diaminobenzidine tetrahydrochloride (Sigma, St Louis, MO), diluted in 12 ml of Tris buffer at pH 7.6, for 2 min. All slides were lightly counterstained with hematoxylin for 30 s before dehydration and mounting. Tissue sections stained without a primary antibody served as a negative control. Positive and negative controls were used for each section. Under microscopy, six fields were randomly selected from every sample, and independent observers performed cell counting in a blind manner. The expression rate ¼ (number of total positive cells/total number of cells) Â 100%.
Apoptotic cells in tumor tissue sections were quantified using In Situ Apoptosis Detection Kit (Roche). Formalinfixed paraffin-embedded sections were dewaxed before being permeabilized with proteinase K for 15 min at room temperature. Endogenous peroxidase was blocked using 3% H 2 O 2 , and sections were incubated with equilibration buffer and TdT enzyme. Finally, the sections were incubated with anti-digoxigenin-peroxidase conjugate. Peroxidase activity in each tissue section was shown by the application of DAB. Under microscopy, six fields were randomly selected from every sample, and independent observers performed cell counting in a blind manner. The apoptotic rate ¼ (number of total apoptotic cells/total number of cells) Â 100%.
Statistical analysis
Values were expressed as mean ± s.d., and statistical analysis of the results was carried out by one-way analysis of the variance followed by Duncan's new multiple range method or Newman-Keuls test. P-values o0.05 were considered significant. Figure 1 . The successful construction of ZD55-IL-18 was confirmed by restrictive enzyme digestion assay and sequence assay. The purified virus preparations were subjected to PCR and restriction digestion to confirm correct modification to the Ad genome and the absence of wild-type adenoviruses contamination.
Results
Construction of ZD55-IL-18
Initially, a fragment of E1B region from 2269 to 3327 was deleted from a recombinant Ad vector and an oligonucleotide containing stop codons and a BglII clone site were incorporated into this region. On the basis of this new vector, a recombinant adenovirus named ZD55-IL-18 was obtained by cloning the IL-18 expression cassette containing CMV promoter þ IL-18 þ SV40 polyA into the BglII site. The schematic diagram of recombinant adenovirus ZD55-IL-18 is illustrated in
Potent cytopathic effect induced by ZD55-IL-18
To explore whether IL-18 could sensitize tumor cells to ZD55-triggered death, A375 cancer cells were infected with ZD55-IL-18, ZD55-EGFP and Ad-IL-18 at various MOIs as indicated. Cells were stained with crystal violet 7 days later. As shown in Figure 2 , marked cytopathic effect was observed in tumor cell lines infected with ZD55-IL-18 even at very low MOI (0.1-1), as compared with cells infected with ZD55-EGFP or Ad-IL-18. These results indicated that ZD55-IL-18 inhibited the growth of tumor cells more effectively than Ad-IL-18 therapy or ZD55-EGFP virus therapy alone.
Effect of ZD55-IL-18 on tumor cell apoptosis TUNEL analysis indicated that, as shown in Figure 3 , A375 cells infected with ZD55-IL-18 at a MOI of 10 showed a higher apoptotic rate (62.73 ± 2.93%) than that in the cancer cells infected with Ad-IL-18 (22.54±3.26%) and ZD55-EGFP (50.66 ± 1.79%), whereas the apoptotic rates of the control cells treated with PBS were only (12.23 ± 2.83%). Figure 1 The schematic diagram of recombinant adenoviruses ZD55-IL-18. In ZD55-IL-18, the E1B 55-kDa gene was replaced by the IL-18 expression cassette. ZD55-IL-18 was generated in HEK293 cells by homologous recombination between pZD55-IL-18 and the adenovirus packaging plasmid pBHGE3. (Figure 4) . However, knock-in of IL-18 enhanced this effect. It is interesting to note that the tumors infected with ZD55-IL-18 shrunk in size between weeks 5 and 7, whereas in all other treatment groups tumor volume increased, which may be due to the prolonged effect of IL-18 and direct anticancer effect of oncolytic adenovirus as compared with ZD55-EGFP and AD-IL-18.
Role of oncolytic Ad with IL-18 in inhibition of angiogenesis
We also determined the presence of apoptotic cells in the tumor sections by TUNEL staining, which showed more positive cells in ZD55-IL-18-treated group than in control treatment group. Although ZD55-EGFP-treated and AD-IL-18-treated groups showed an increase in the number of apoptotic cells, apoptosis was lower than in ZD55-IL-18 group ( Figure 5 ).
Immunohistochemistry analysis of IL-18, CD34, VEGF and E1A
To verify that the therapeutic effect was due to induction of IL-18 gene and inhibition of CD34 and VEGF expression, the tumors were frozen and were subjected to immunohistochemical analysis of IL-18, CD34, VEGF and E1A. As shown in Figure 6 , IL-18 staining showed a marked increase in ZD55-IL-18 and Ad-IL-18-treated groups, which was significant compared with ZD55-EGFP-and PBS-treated groups. Furthermore, results showed that ZD55-IL-18 suppressed the CD34 and VEGF expression more potently than the PBS treatment. Moreover, as shown in Figure 6 , E1A expressions were detected only in ZD55-IL-18 and ZD55-EGFP treatment groups but not in Ad-IL-18 treatment group, which indicated that ZD55-IL-18 could replicate in tumor cells.
Discussion
IL-18 is considered as a promising anticancer agent. A phase I clinical trial of IL-18 treatment for melanoma has been conducted and a stable clinical response shown. 15 However, the systemic application of recombinant IL-18 may be limited by the facts that only large amounts of IL-18 elicit antitumor activity but simultaneously elicit dose-dependent adverse effects. On the other hand, virotherapy for cancer with oncolytic viruses is designed to selectively replicate and kill tumor cells using viral mutants to control viral replication. 22, 23 More than 10 clinical trials involving more than 200 patients with cancer have been conducted with Onyx-015, the first oncolytic virus described. 24, 25 The reported results showed that oncolytic viruses administrated intratumorally, intraperitoneally and intravenously were well tolerated. However, the efficacy of Onyx-015 as a single agent is also limited because of inefficient cell lysis and release of their progeny. 26 Indeed, a clinical trial with Onyx-015 showed that even though the virus was present and replicating in tumors for as long as a week after its intratumoral injection, no obvious tumor necrosis or apoptosis was detected, 27 suggesting that its replication alone may be insufficient to induce cell death. We hypothesized that integrating IL-18 gene therapy with an oncolytic adenovector will overcome the weaknesses of the IL-18 therapy and virotherapy used individually. An oncolytic virus armed with IL-18 gene will replicate in tumor cells, thereby increasing the IL-18 expression in tumor cells and the local IL-18 concentrations in the tumor microenvironment. As the levels of secretion of IL-18 correlates well with the strength of its antitumor activity, 28 an IL-18-expressing oncolytic adenovector may have potent antitumor activity with minimal toxicity to normal cells.
Angiogenesis is essential for tumor growth and most melanoma are characterized by hypervascularity. 29 Angiogenesis can be inhibited by inhibition of expression and production of angiogenic factors. 30 It has been shown that VEGF plays important roles in eliciting angiogenesis in melanoma 31 and abrogating the VEGF pathway can lead to the inhibition of tumor growth through suppression of angiogenesis. 32 The antitumor effect of ZD55-IL-18 in this study was expected to have been partly mediated through inhibition of tumor vessel formation, because IL-18 has been shown to have a role in antiangiogenesis. Cao et al. 33 reported that IL-18 suppressed melanoma angiogenesis and proposed that IL-18 plays an important role in the antitumor effect through its antiangiogenic activity. However, IL-18 has, by contrast, been shown to induce VEGF, promote endothelial cell migration and increase vascular tube formation in vitro and in vivo. 34, 35 Kim et al. 36 showed that IL-18 stimulates the proangiogenic factor, thrombospondin-1, production through the JNK pathway. The reason for the discrepancy in these results remains unclear, and these discrepant observations prompted us to investigate whether ZD55-IL-18 can downregulate the expression of VEGF and have antiangiogenic effects.
Our studies have shown that VEGF expression in the tumor mass was more greatly decreased when tumors were treated with ZD55-IL-18 than when treated with ZD55-EGFP or Ad-IL-18. This reduction in VEGF may in turn further decrease angiogenesis, which was highlighted by the endothelial marker, CD34 expression. ZD55-IL-18 showed more prominent suppression of the expression of CD34 than ZD55-EGFP or Ad-IL-18 did. To our surprise, the significant reductions of VEGF and CD34 were observed in ZD55-EGFP treatment groups compared with Ad-IL-18 groups. Moreover, ZD55-EGFP probably has intrinsic antiangiogenic effect rather than mere induction of IL-18 expression, because ZD55-EGFP evoked the stronger antiangiogenic effect but feebler IL-18 expression than Ad-IL-18 did. This means that the oncolytic virus directly suppresses VEGF expression and angiogenesis. This may be explained by the toxicity of replicating viruses to endothelial cells. Zhang et al. 37 and Chen et al., 38 respectively, reported similar results in gastric cancer and prostate cancer animal models. The therapeutic strategy of combining oncolytic Ad with IL-18 could decrease vascular dissemination from the infected tumor site, resulting in oncolytic Ad sequestration within the tumor and increase in local IL-18 expression, which ultimately could lead to a long-lasting therapeutic effect and a decrease in systemic toxicity.
Previous reports suggested that IL-18 was not able to directly induce apoptosis in cancer cells in vitro, 39 except for the report by Okano and Yamada, 6 which showed that canine IL-18 directly induces apoptosis in a canine carcinoma cell line. In this study, we provide an evidence that the strong antitumor activity of ZD55-IL-18 is partly due to dramatic induction of tumor cell apoptosis in treated tumors. Our data indicated that ZD55-IL-18 had much stronger apoptosis-induced activity in melanoma cells and tumors than ZD55-EGFP and Ad-IL-18. ZD55-EGFP had much stronger apoptosis-induced activity in melanoma cells and tumors than Ad-IL-18, which also showed a mild effect in reducing apoptosis. This means that induction of IL-18 expression seems to be a minor part of the mechanisms in inducing melanoma apoptosis by ZD55-EGFP and the direct induction of apoptosis is a major mechanism. Adenovirus E1A is known to induce apoptosis in certain cancer cells by the accumulation of p53 and activation of procaspase-8. 40, 41 Moreover, the virus-gene integration into the genomic DNA of cancer cells and the high-level expression could lead to increased susceptibility to apoptosis. 42 Therefore, we speculate that coordinated triggering of apoptosis by the IL-18 and E1A genes in the ZD55-IL-18 may be the mechanism of enhancing killing of cancer cells by ZD55-IL-18. Our speculations are in agreement with our data showing that ZD55-IL-18 achieved antitumoral efficacy much more superior to that of ZD55-EGFP by inclusion of IL-18, and superior to that of Ad-IL-18 by viral replication.
Taken collectively, our results showed that oncolytic adenovirus armed with IL-18 gene is a novel angiogenesis inhibitor and an apoptosis inducer that is sufficiently potent to suppress angiogenesis and tumor growth of melanoma. This offers the prospect of improving the efficacy of oncolytic viruses and reducing the side effects of IL-18. ZD55-IL-18 may represent a potentially exciting new treatment paradigm for melanoma.
Abbreviations EGFP, enhanced green fluorescent protein; IL-18, interleukin 18; MOI, multiplicity of infection; TUNEL, TdTmediated dUTP-biotin nick end-labeling assay; VEGF, vascular endothelial growth factor.
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